Latest market price
68.50
+1.46+2.18%
TA
Loading chart...
Snapshot
| Index | — | P/E | 19.80 | EPS (ttm) | 3.46 | Insider Own | 4.97% | Shs Outstand | 49.11M | Perf Week | 1.54% |
| Market Cap | 3.36B | Forward P/E | 21.27 | EPS next Y | 3.22 | Insider Trans | 0.10% | Shs Float | 47.94M | Perf Month | 4.23% |
| Enterprise Value | 4.62B | PEG | — | EPS next Q | 1.18 | Short Float | 4.65% | Perf Quarter | -8.13% | ||
| Income | 167.00M | P/S | 7.75 | EPS this Y | 29.25% | Short Ratio | 6.13 | Perf Half Y | -9.52% | ||
| Sales | 434.00M | P/B | 2.13 | EPS next Y | -17.31% | ROA | 5.63% | Short Interest | 2.23M | Perf YTD | -10.31% |
| Book/sh | 32.15 | P/C | 112.13 | EPS next 5Y | — | ROE | 10.96% | 52W High | 91.38 -25.04% | Perf Year | -8.97% |
| Cash/sh | 0.61 | P/FCF | 14.25 | EPS past 3/5Y | 80.92% -0.07% | ROIC | 6.90% | 52W Low | 63.51 7.86% | Perf 3Y | 35.97% |
| Dividend Est. | 3.76 (5.49%) | EV/EBITDA | 14.62 | Sales past 3/5Y | 10.88% 2.62% | Gross Margin | 56.25% | Volatility | 1.94% 2.06% | Perf 5Y | 22.50% |
| Dividend TTM | 3.70 (5.40%) | EV/Sales | 10.64 | EPS Y/Y TTM | 10.54% | Oper. Margin | 45.34% | ATR (14) | 1.47 | Perf 10Y | -12.12% |
| Dividend Ex-Date | Sep 30, 2026 | Quick Ratio | 0.59 | Sales Y/Y TTM | 24.36% | Profit Margin | 38.47% | RSI (14) | 57.84 | Recom | 2.74 |
| Dividend Gr. 3/5Y | 0.37% -3.77% | Current Ratio | 0.59 | EPS Q/Q | 50.63% | SMA20 | 3.82% | Beta | 0.52 | Target Price | 77.40 |
| Payout | 105.26% | Debt/Eq | 0.81 | Sales Q/Q | 32.97% | SMA50 | 0.73% | Rel Volume | 0.88 | Prev Close | 67.04 |
| Employees | 32 | LT Debt/Eq | 0.54 | Earnings | Nov 09 | SMA200 | -10.25% | Avg Volume | 336.34K | Price | 68.50 |
| IPO Date | Oct 09, 1991 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 41.11% -1.02% | Net Debt/EBITDA | 3.97 | Volume | 296,266 | Change | 2.18% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Reiterated | Wells Fargo | Equal Weight | $78 → $68 |
| Sep-09-26 | Initiated | Huntington | Outperform | $79 |
| Sep-02-26 | Reiterated | Truist Securities | Buy | $81 → $80 |
| Sep-01-26 | Reiterated | Wells Fargo | Equal Weight | $86 → $78 |
| Jun-25-26 | Reiterated | Deutsche Bank | Hold | $80 |
| Jun-15-26 | Reiterated | BMO Capital | Outperform | $61 → $80 |
| Jun-12-26 | Reiterated | Truist Securities | Buy | $83 → $81 |
| Mar-27-26 | Reiterated | Wells Fargo | Equal Weight | $85 → $86 |
| Jan-20-26 | Reiterated | National Bank | $90 → $85 | |
| Jan-05-26 | Reiterated | Cantor Fitzgerald | Neutral | $87 → $85 |
Latest News· Times ET
Oct-28-26
Oct-19-26
Oct-19-2608:35AM
Oct-17-26
04:32AM
Oct-15-26
Oct-14-26
Oct-14-2608:45AM
Oct-10-26
Oct-07-26
Oct-07-2606:00AM
Oct-03-26
Oct-03-2604:28AM
Oct-01-26
Sep-30-26
Sep-30-2612:15PM
Sep-28-26
Sep-28-2608:31AM
Sep-24-26
Sep-24-2603:11PM
12:41PM
Company
Established in 1991, National Health Investors, Inc. (NYSE: NHI) operates as a real estate investment trust (REIT) primarily focused on providing capital for senior living and medical real estate assets. The company facilitates this through diverse financing options, including sale-leaseback arrangements, joint ventures, and various debt instruments such as mortgage and mezzanine loans, targeting properties that cater to both essential care needs and discretionary services. NHI's broad holdings feature independent living, assisted living, and memory care facilities, as well as entrance-fee retirement communities, skilled nursing homes, medical office complexes, and specialized hospitals.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 434 | 379 | 335 | 320 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 190 | 240 | 11 | 12 | — | — | — | — | — | |
| Gross Profit | 244 | 139 | 324 | 308 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 15 | 0 | 22 | 20 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 33 | -56 | 118 | 110 | — | — | — | — | — | |
| Operating Income | 196 | 195 | 184 | 179 | — | — | — | — | — | |
| Interest Expense | 44 | 57 | 56 | 56 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 13 | 3 | 9 | 11 | — | — | — | — | — | |
| Net Income Before Taxes | 166 | 141 | 137 | 134 | — | — | — | — | — | |
| Income Taxes | 1 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 167 | 142 | 138 | 136 | — | — | — | — | — | |
| Net Income From Continuing Operations | 165 | 141 | 137 | 134 | — | — | — | — | — | |
| Net Income | 167 | 142 | 138 | 136 | — | — | — | — | — | |
| EPS (Recurring) | 3.47 | 3.03 | 3.14 | 3.13 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.47 | 3.03 | 3.14 | 3.13 | — | — | — | — | — | |
| EPS (Diluted) | 3.46 | 3.02 | 3.13 | 3.13 | — | — | — | — | — | |
| EBITDA | 316 | 282 | 264 | 260 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 19.80 | 25.29 | 22.14 | 17.84 | — | — | — | — | — | |
| Price To Sales Ratio | 7.58 | 9.47 | 9.10 | 7.50 | — | — | — | — | — | |
| Gross Margin | 56.22 | 36.68 | 96.72 | 96.25 | — | — | — | — | — | |
| Operating Margin | 45.16 | 51.45 | 54.93 | 55.94 | — | — | — | — | — | |
| Net Margin | 38.48 | 37.47 | 41.19 | 42.50 | — | — | — | — | — | |
| Shares Outstanding | 48 | 47 | 44 | 43 | — | — | — | — | — | |
| Market Capitalization | 3,288 | 3,589 | 3,049 | 2,402 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MCCABE ROBERT A JR | Director | Jun 15 '26 | Buy | 71.65 | 890 | 63,767 | 44,159 | Jun 15 |
| Mendelsohn D. Eric | CEO and President | Jun 05 '26 | Buy | 68.84 | 1,500 | 103,260 | 133,316 | Jun 05 |
| Spaid John L | CFO/EVP Finance | Mar 03 '26 | Option Exercise | 73.34 | 15,000 | 1,100,100 | 69,849 | Mar 05 |
| Travis David L | SVP/Chief Accounting Officer | Feb 23 '26 | Option Exercise | 57.76 | 25,000 | 1,444,000 | 57,122 | Feb 25 |
| PASCOE KEVIN CARLTON | Chief Investment Officer | Feb 23 '26 | Option Exercise | 57.76 | 8,500 | 490,960 | 74,765 | Feb 25 |
| Mendelsohn D. Eric | CEO and President | Feb 23 '26 | Option Exercise | 57.76 | 13,334 | 770,172 | 128,784 | Feb 25 |
| Spaid John L | CFO/EVP Finance | Feb 23 '26 | Option Exercise | 57.76 | 8,500 | 490,960 | 57,182 | Feb 25 |
| COLDEN TRACY M J | Director | Feb 19 '26 | Option Exercise | 73.34 | 10,000 | 733,400 | 19,857 | Feb 23 |
| Mendelsohn D. Eric | CEO and President | Feb 17 '26 | Option Exercise | 73.34 | 25,000 | 1,833,500 | 137,505 | Feb 19 |
| Jobe James R | Director | Feb 17 '26 | Option Exercise | 73.34 | 10,000 | 733,400 | 41,555 | Feb 19 |
| MCCABE ROBERT A JR | Director | Feb 12 '26 | Option Exercise | 73.34 | 10,000 | 733,400 | 50,181 | Feb 17 |
| PASCOE KEVIN CARLTON | Chief Investment Officer | Feb 11 '26 | Option Exercise | 73.34 | 15,000 | 1,100,100 | 79,728 | Feb 13 |
| Travis David L | SVP/Chief Accounting Officer | Feb 09 '26 | Option Exercise | 54.30 | 37,200 | 2,019,852 | 60,990 | Feb 11 |
| Todd Candice W | Director | Feb 05 '26 | Option Exercise | 73.34 | 10,000 | 733,400 | 10,000 | Feb 09 |
| Gaines Kristin Sallee | SVP/Chief Transaction Officer | Feb 01 '26 | Option Exercise | 66.04 | 98,181 | 6,483,575 | 116,944 | Feb 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.